STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
- PMID: 11526490
- DOI: 10.1038/sj.onc.1204704
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
Abstract
Mutations in the c-KIT receptor occur somatically in many sporadic Gastrointestinal Stromal Tumors (GIST), and similar mutations have been identified at the germline level in kindreds with multiple GISTs. These mutations activate the tyrosine kinase activity of c-KIT and induce constitutive signaling. To investigate the function of activated c-KIT in GIST, we established a human GIST cell line, GIST882, which expresses an activating KIT mutation (K642E) in the first part of the cytoplasmic split tyrosine kinase domain. Notably, the K642E substitution is encoded by a homozygous exon 13 missense mutation, and, therefore, GIST882 cells do not express native KIT. GIST882 c-KIT protein is constitutively tyrosine phosphorylated, but tyrosine phosphorylation was rapidly and completely abolished after incubating the cells with the selective tyrosine kinase inhibitor STI571. Furthermore, GIST882 cells evidenced decreased proliferation and the onset of apoptotic cell death after prolonged incubation with STI571. Similar results were obtained after administering STI571 to a primary GIST cell culture that expressed a c-KIT exon 11 juxtamembrane mutation (K558NP). These cell-culture-based studies support an important role for c-KIT signaling in GIST and suggest therapeutic potential for STI571 in patients afflicted by this chemoresistant tumor.
Similar articles
-
Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.Oncol Rep. 2005 Sep;14(3):645-50. Oncol Rep. 2005. PMID: 16077968
-
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Semin Oncol. 2001. PMID: 11740803 Review.
-
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).Oncogene. 2004 May 13;23(22):3999-4006. doi: 10.1038/sj.onc.1207525. Oncogene. 2004. PMID: 15007386
-
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.Cancer Res. 2002 Sep 1;62(17):4879-83. Cancer Res. 2002. PMID: 12208734
-
Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).Gene. 2007 Oct 15;401(1-2):38-45. doi: 10.1016/j.gene.2007.06.017. Epub 2007 Jul 3. Gene. 2007. PMID: 17659849 Review.
Cited by
-
FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.Oncotarget. 2015 Aug 21;6(24):20215-30. doi: 10.18632/oncotarget.4046. Oncotarget. 2015. PMID: 26036639 Free PMC article.
-
A clinical and biological overview of gastrointestinal stromal tumors.Med Oncol. 2005;22(1):1-10. doi: 10.1385/MO:22:1:001. Med Oncol. 2005. PMID: 15750190 Review.
-
Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.Br J Cancer. 2010 Oct 26;103(9):1422-31. doi: 10.1038/sj.bjc.6605906. Epub 2010 Sep 21. Br J Cancer. 2010. PMID: 20859288 Free PMC article.
-
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.Mol Aspects Med. 2010 Apr;31(2):135-44. doi: 10.1016/j.mam.2010.02.003. Epub 2010 Feb 20. Mol Aspects Med. 2010. PMID: 20176047 Free PMC article. Review.
-
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.BMC Endocr Disord. 2018 Nov 3;18(1):77. doi: 10.1186/s12902-018-0303-x. BMC Endocr Disord. 2018. PMID: 30390651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials